Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis
- PMID: 31883829
- DOI: 10.1016/j.jaut.2019.102379
Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis
Abstract
Rheumatoid Arthritis (RA) represents a chronic T cell-mediated inflammatory autoimmune disease. Studies have shown that epigenetic mechanisms contribute to the pathogenesis of RA. Histone deacetylases (HDACs) represent one important group of epigenetic regulators. However, the role of individual HDAC members for the pathogenesis of arthritis is still unknown. In this study we demonstrate that mice with a T cell-specific deletion of HDAC1 (HDAC1-cKO) are resistant to the development of Collagen-induced arthritis (CIA), whereas the antibody response to collagen type II was undisturbed, indicating an unaltered T cell-mediated B cell activation. The inflammatory cytokines IL-17 and IL-6 were significantly decreased in sera of HDAC1-cKO mice. IL-6 treated HDAC1-deficient CD4+ T cells showed an impaired upregulation of CCR6. Selective inhibition of class I HDACs with the HDAC inhibitor MS-275 under Th17-skewing conditions inhibited the upregulation of chemokine receptor 6 (CCR6) in mouse and human CD4+ T cells. Accordingly, analysis of human RNA-sequencing (RNA-seq) data and histological analysis of synovial tissue samples from human RA patients revealed the existence of CD4+CCR6+ cells with enhanced HDAC1 expression. Our data indicate a key role for HDAC1 for the pathogenesis of CIA and suggest that HDAC1 and other class I HDACs might be promising targets of selective HDAC inhibitors (HDACi) for the treatment of RA.
Keywords: CCR6; HDACs; Histone deacetylases; Rheumatoid arthritis; T cells.
Copyright © 2019. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest None. This research has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement n°115142 (BTCure), and grant agreement n(o)777357 (RTCure) resources of which are composed of financial contribution from the European Union's Framework Programmes and EFPIA companies' in kind contribution. The work has been supported by the Austrian Science Fund (FWF) project F26193 (to WE) and the FWF special research program SFB F70 (subproject F7003 to MB, F7004 to NB and F7005 to WE).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous